Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension: 30 Years Experience from China

Yong Lv,Daiming Fan,Guohong Han
DOI: https://doi.org/10.1111/liv.15313
IF: 8.754
2023-01-01
Liver International
Abstract:Liver diseases are a major cause of illness and death worldwide. In China, liver diseases, primarily viral hepatitis, affect approximately 300 million people, thus having a major impact on the global burden of liver diseases. Portal hypertension is the most severe complication of chronic liver diseases, including ascites, hepatic encephalopathy and bleeding from gastroesophageal varices. Transjugular intrahepatic portosystemic shunt (TIPS) represents a very effective treatment of these complications. Since its introduction 30 years ago in China, the use of TIPS has evolved and has played an increasingly important role in the management of the complications of portal hypertension. This review will focus on the history, current application and management of complications of TIPS in China.
What problem does this paper attempt to address?